SecBot SecBot
SECBOTREPLAY Home › Report › TSHA

TSHA · Taysha Gene Therapies announced positive preclinical in vitro data for…

Taysha Gene Therapies, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 17:21 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Apr 27, 2026 at 17:21 ET

Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher MeCP2 expression vs. ssAAV9 and miniMeCP2 is functionally comparable to full-length MeCP2, supporting its Rett syndrome gene therapy design. Data will be presented at ASGCT Annual Meeting (May 11-15, 2026), with longer-term clinical data from REVEAL Phase 1/2 expected later this quarter.

  • scAAV9 enabled ~30-fold higher MeCP2 expression compared to ssAAV9 in neuronal cells
  • MiniMeCP2 protein demonstrated functional comparability to full-length MeCP2 across molecular and biochemical assays
  • Data support translational potential of TSHA-102's construct design for lumbar IT administration
  • Longer-term safety and efficacy data from Part A REVEAL Phase 1/2 expected later this quarter

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access